Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ansaripour, Amir
33  Ergebnisse:
Personensuche X
?
1

Early Cost-Effectiveness and Price Threshold Analyses of Re..:

Javanbakht, Mehdi ; Fishman, Jesse ; Moloney, Eoin..
PharmacoEconomics - Open.  7 (2022)  1 - p. 93-110 , 2022
Link: https://doi.org/10.1007/..
 
?
2

Cost-effectiveness of baloxavir marboxil compared with lani..:

Dronova, Mariia ; Ikeoka, Hidetoshi ; Itsumura, Naoya...
Current Medical Research and Opinion.  37 (2021)  7 - p. 1135-1148 , 2021
Link: https://doi.org/10.1080/..
 
?
3

Cost-effectiveness of baloxavir marboxil compared to lanina..:

Skrzeczek, Aleksandra ; Ikeoka, Hidetoshi ; Hirotsu, Nobuo...
Journal of Infection and Chemotherapy.  27 (2021)  2 - p. 296-305 , 2021
Link: https://doi.org/10.1016/..
 
?
4

Budget Impact of the Vest™ High Frequency Chest Wall Oscill..:

Ansaripour, Amir ; Roehrich, Kari ; Mashayekhi, Atefeh...
PharmacoEconomics - Open.  6 (2021)  2 - p. 169-178 , 2021
Link: https://doi.org/10.1007/..
 
?
5

Severity-Adjusted Probability of Being Cost Effective:

Versteegh, Matthijs M. ; Ramos, Isaac Corro ; Buyukkaramikli, Nasuh C....
PharmacoEconomics.  37 (2019)  9 - p. 1155-1163 , 2019
Link: https://doi.org/10.1007/..
 
?
6

Author Correction to: Adjuvant Trastuzumab Therapy for Earl..:

Ansaripour, Amir ; Uyl-de Groot, Carin A. ; Redekop, W. Ken
PharmacoEconomics.  36 (2018)  4 - p. 505-505 , 2018
Link: https://doi.org/10.1007/..
 
?
7

Use of data-mining to support real-world cost analyses: An ..:

Ansaripour, Amir ; Zendehdel, Kazem ; Tadayon, Niki...
PLOS ONE.  13 (2018)  10 - p. e0205079 , 2018
Link: https://doi.org/10.1371/..
 
?
8

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for ..:

Ansaripour, Amir ; Uyl-de Groot, Carin A. ; Redekop, W. Ken
PharmacoEconomics.  36 (2018)  3 - p. 381-382 , 2018
Link: https://doi.org/10.1007/..
 
?
9

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast..:

Ansaripour, Amir ; Uyl-de Groot, Carin A. ; Redekop, W. Ken
PharmacoEconomics.  36 (2017)  1 - p. 91-103 , 2017
Link: https://doi.org/10.1007/..
 
?
10

Which is more important for doctors in a middle-income coun..:

Ansaripour, Amir ; Uyl-de Groot, Carin A. ; Foroozanfar, Mohammad..
Journal of Cancer Policy.  9 (2016)  - p. 8-13 , 2016
Link: https://doi.org/10.1016/..
 
?
11

The Drug Reimbursement Decision-Making System in Iran:

Ansaripour, Amir ; Uyl-de Groot, Carin A. ; Steenhoek, Adri.
Value in Health Regional Issues.  3 (2014)  - p. 174-181 , 2014
Link: https://doi.org/10.1016/..
 
?
12

Early Cost-Effectiveness and Price Threshold Analyses of Re..:

Javanbakht, Mehdi ; Fishman, Jesse ; Moloney, Eoin..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929016/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Budget Impact of the Vest™ High Frequency Chest Wall Oscill..:

Ansaripour, Amir ; Roehrich, Kari ; Mashayekhi, Atefeh...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864050/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
14

Severity-Adjusted Probability of Being Cost Effective:

Versteegh, M.M. (Matthijs) ; Corro Ramos, I. (Isaac) ; Buyukkaramikli, N.C...
http://repub.eur.nl/pub/116656.  , 2019
Link: http://repub.eur.nl/pub/..
 
?
15

Severity-Adjusted Probability of Being Cost Effective:

Versteegh, Matthijs ; Corro Ramos, Isaac ; Buyukkaramikli, Nasuh...
Versteegh , M , Corro Ramos , I , Buyukkaramikli , N , Ansaripour , A , Reckers - Droog , V & Brouwer , W 2019 , ' Severity-Adjusted Probability of Being Cost Effective ' , Pharmacoeconomics (Print) , vol. 37 , pp. 1155-1163 . https://doi.org/10.1007/s40273-019-00810-8.  , 2019
Link: https://pure.eur.nl/en/p..
 
1-15